Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice

Citation
Tu. Yamaguchi et al., Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice, BRAIN RES, 909(1-2), 2001, pp. 121-126
Citations number
34
Categorie Soggetti
Neurosciences & Behavoir
Journal title
BRAIN RESEARCH
ISSN journal
00068993 → ACNP
Volume
909
Issue
1-2
Year of publication
2001
Pages
121 - 126
Database
ISI
SICI code
0006-8993(20010803)909:1-2<121:EC2AN>2.0.ZU;2-R
Abstract
In the present study, we examined the effects of endogenous ligand 2-arachi donoylglycerol (2-AG) on naloxone-precipitated withdrawal in morphine-depen dent mice, in comparison with that of two cannabinoid agonists, an ingredie nt of Cannabis sativa Delta (s)-tetrahydrocannabinol (Delta (8)-THC) and th e synthetic cannabinoid CB1 receptor agonist HU-210. 2-AG at a dose of 10 m ug per mouse (i.c.v.) significantly inhibited both jumping and forepaw trem or as si ns of withdrawal following naloxone challenge in morphine-dependen t mice. Furthermore, both Delta (8)-THC and HU-210 significantly attenuated these symptoms of withdrawal in morphine-dependent mice. Therefore, it is suggested that inactivation of the endogenous cannabinoid system is related to the induction of withdrawal syndrome in morphine-dependent mice. Moreov er, hyperlocomotor activity in morphine-dependent mice was markedly increas ed by Delta (8)-THC 10 mg/ka, which had no effect in naive mice. This findi ng suggested that in morphine dependence, upregulation of cannabinoid CB1 r eceptors occurred. Non-psychoactive CB1 receptor agonists or accelerators o f endocannabinoid synthesis may be potential as therapeutic drugs for opiat e withdrawal symptoms. (C) 2001 Elsevier Science B.V. All rights reserved.